Valuation: Sera Prognostics, Inc.

Market Cap 82.23M 71.47M 66.72M 61.25M 115M 7.84B 118M 787M 308M 3.91B 309M 302M 12.89B P/E 2026 *
-3.21x
P/E 2027 * -3.75x
Enterprise Value 82.23M 71.47M 66.72M 61.25M 115M 7.84B 118M 787M 308M 3.91B 309M 302M 12.89B EV / Sales 2026 *
227x
EV / Sales 2027 * 30.7x
Free-Float
85.93%
Yield 2026 *
-
Yield 2027 * -
1 day+2.94%
1 week+2.44%
Current month+2.94%
1 month+5.00%
3 months+9.95%
6 months-25.53%
Current year-28.81%
1 week 1.97
Extreme 1.97
2.19
1 month 1.79
Extreme 1.7901
2.3
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
13.51
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Free

Director

62,657 0.1641%
10/7/26 Free

Director

62,697 0.1642%
10/7/26 Free

Director

61,416 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%+2.44%-22.22%-28.81% 82.23M
+0.79%+1.54%+18.68%+17.35% 23.65B
-0.64%+1.10%+26.63% - 18.35B
-1.25%+5.26%+15.73%-29.88% 3.52B
-4.31%-6.20%+18.52%+1.14% 2.33B
+1.36%+4.86%-23.00%-34.19% 2.21B
+7.25%+7.84%-28.92% - 1.74B
+2.00%+5.80%0.00%+5.41% 1.58B
+1.79%+5.04%-10.63%+4.08% 1.36B
-11.94%+0.32%+113.70%+256.94% 1.09B
Average -0.20%+3.77%+10.85%+24.01% 5.59B
Weighted average by Cap. +0.02%+1.95%+18.52%+14.61%

Financials

2026 *2027 *
Net sales 362K 315K 294K 270K 509K 34.55M 518K 3.47M 1.36M 17.23M 1.36M 1.33M 56.83M 2.68M 2.32M 2.17M 1.99M 3.76M 255M 3.82M 25.59M 10.02M 127M 10.05M 9.83M 419M
Net income -33.26M -28.91M -26.99M -24.78M -46.72M -3.17B -47.53M -318M -125M -1.58B -125M -122M -5.21B -29.98M -26.05M -24.33M -22.33M -42.11M -2.86B -42.84M -287M -112M -1.42B -113M -110M -4.7B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
03/08/26 USD 2.100 +2.94% 15,272
31/07/26 USD 2.040 -2.86% 24,658
30/07/26 USD 2.100 +2.44% 79,024
29/07/26 USD 2.050 +0.99% 11,192
28/07/26 USD 2.030 -0.98% 26,133
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.100USD
Average target price
5.500USD
Spread / Average Target
+161.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock